MIAMI, Oct. 20, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF. [Read more…]
FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy
First Reported eIND Issued for Outpatient COVID-19 Therapy
Miami, FL (August 6, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. [Read more…]
First Dosing in Plexoval Exosome Wound Healing Human Study
Highlights
- First human dosing of Plexaris™ has occurred in Exopharm’s PLEXOVAL Study
- PLEXOVAL is a world-first study using a cell free, platelet-derived exosome product manufactured using Exopharm’s proprietary LEAP Technology for wound healing
- Other pre-clinical development progress will be reported over coming months
MELBOURNE, Australia – Jan. 29, 2020 11:00 UTC — Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial. Further participants are expected to soon follow in this study that involves up to 20 participants. [Read more…]
Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs
Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.
BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. [Read more…]
PLEXOVAL Exosome Wound Healing Human Study Starts
-
A world-first study using cell free exosome product manufactured using Exopharm’s LEAP Technology
-
Study sites at the Royal Melbourne Hospital and Australian Red Cross Blood Service
-
Results by mid 2020
26 August 2019, Melbourne, Australia: Regenerative medicine company Exopharm Limited (ASX:EX1) announces the start of the PLEXOVAL Phase 1 study, the first human clinical trial using exosomes for wound healing. [Read more…]
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 12
- Next Page »